Autoantibodies: Opportunities for Early Cancer Detection (Q38656064)

5 September 2017

title

Autoantibodies: Opportunities for Early Cancer Detection (English)

1 reference

5 September 2017

1 reference

Isabel K Macdonald

1

1 reference

5 September 2017

Celine B Parsy-Kowalska

series ordinal

2

1 reference

5 September 2017

Caroline J Chapman

series ordinal

3

1 reference

5 September 2017

publication date

6 March 2017

1 reference

5 September 2017

1 reference

5 September 2017

volume

3

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

198-213

1 reference

Reduced lung-cancer mortality with low-dose computed tomographic screening

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The case for early detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumour specific T-like antigen of human breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immunity to transplanted tumour: the effect of tumour extracts on the growth of homologous tumours in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumour-specific immunity against spontneous rat tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The Laboratory Diagnosis of Autoimmune Encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Clinically Meaningful Use of Blood Tumor Markers in Oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Circulating nucleic acids: An analysis of their occurrence in malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies in early breast cancer: a stage-related phenomenon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immunobiomarkers in small cell lung cancer: potential early cancer signals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The sentinel within: exploiting the immune system for cancer biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Capitalizing on the immunogenicity of dying tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Naturally occurring B-cell responses to breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

CD20 B cells: the other tumor-infiltrating lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The humoral immune system has a key prognostic impact in node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

CD20 tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8 T cells promote favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Genetic disruption of CD8 Treg activity enhances the immune response to viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Inhibition of follicular T-helper cells by CD8( ) regulatory T cells is essential for self tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The natural history of chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Major histocompatibility complex expression on human, male germ cells: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

HLA antigen expression and induction by γ-interferon in cultured human trophoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies against tumor-related antigens: incidence and biologic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

A systematic review of humoral immune responses against tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Particularities of the vasculature can promote the organ specificity of autoimmune attack.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies to tumor-associated antigens: reporters from the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Plant DNA topoisomerase I is recognized and inhibited by human Scl-70 sera autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibody to RNA polymerase I in scleroderma sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoreactive epitope defined as the anticodon region of alanine transfer RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Injection of anticentromere antibodies in interphase disrupts events required for chromosome movement at mitosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

B-cell epitope spreading in autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Novel roles for the IgG Fc glycan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Association of the autoimmune disease scleroderma with an immunologic response to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Human neoplasms elicit multiple specific immune responses in the autologous host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Serologic autoantibodies as diagnostic cancer biomarkers--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumor-associated autoantibodies as diagnostic and prognostic biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Serum autoantibodies as biomarkers for early cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Profiles of antinuclear antibodies in systemic rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Polymer adhesive surface as flexible generic platform for multiplexed assays biochip production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Development of a multiplex autoantibody test for detection of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibody signatures: progress and perspectives for early cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Current status of circulating protein biomarkers to aid the early detection of lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Serum autoantibody measurement for the detection of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Serum autoantibodies in the early detection of esophageal cancer: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Systematic review: serum autoantibodies in the early detection of gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Survey of autoantibody responses against tumor-associated antigens in thyroid cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Protein production and purification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Reciprocal change with age in antibody to extrinsic and intrinsic antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Validation of new cancer biomarkers: a position statement from the European group on tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

7 January 2021

Breaking a vicious cycle

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

OMICS-based personalized oncology: if it is worth doing, it is worth doing well!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumor antigen expression in melanoma varies according to antigen and stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The abscopal effect associated with a systemic anti-melanoma immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immunologic correlates of the abscopal effect in a patient with melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

PD-1 is a novel regulator of human B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Autoimmune response to PARP and BRCA1/BRCA2 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

PARP inhibitor combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Results of initial low-dose computed tomographic screening for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Clinical validation of an autoantibody test for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Technical validation of an autoantibody test for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Development and validation of a high throughput system for discovery of antigens for autoantibody detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Lung cancer screening with CT: Mayo Clinic experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Factors associated with depressed mood in chronic pain patients: the role of intrapersonal coping resources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Cancer immunoediting: from immunosurveillance to tumor escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Targeting natural killer cells and natural killer T cells in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Tumor-driven evolution of immunosuppressive networks during malignant progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

The immune system. First of two parts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Antibodies elicited by cancer in patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Serum p53 antibodies as early markers of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Ipilimumab: first global approval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Nivolumab: a review of its use in patients with malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.02.003

10.1016/J.TRECAN.2017.02.003

7 January 2021

Identifiers

DOI

1 reference

5 September 2017

1 reference